Thrombin-activatable fibrinolysis inhibitor.
Marx PF.
Curr Med Chem. 2004 Sep;11(17):2335-48. doi: 10.2174/0929867043364586.
Haemostasis.
Arnout J, Hoylaerts MF, Lijnen HR.
Handb Exp Pharmacol. 2006;(176 Pt 2):1-41. doi: 10.1007/3-540-36028-x_1.
Characterization of thrombin activatable fibrinolysis inhibitor in normal and acquired haemostatic dysfunction.
Toh CH.
Blood Coagul Fibrinolysis. 2003 Jun;14 Suppl 1:S69-71. doi: 10.1097/00001721-200306001-00016.
Inflammation and coagulation.
Levi M, van der Poll T.
Crit Care Med. 2010 Feb;38(2 Suppl):S26-34. doi: 10.1097/CCM.0b013e3181c98d21.
Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation.
Colucci M, Semeraro N.
Thromb Res. 2012 Mar;129(3):314-9. doi: 10.1016/j.thromres.2011.10.031. Epub 2011 Nov 21.
Anti-Thrombotic Activity of 3-Deoxysappanchalcone via Inhibiting Platelet Aggregation and Thrombin (FIIa)/Activated Factor X (FXa) Activity.
Han G, Lee J, Bae JS.
Molecules. 2025 Jun 13;30(12):2580. doi: 10.3390/molecules30122580.
Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).
Bouma BN, Marx PF, Mosnier LO, Meijers JC.
Thromb Res. 2001 Mar 1;101(5):329-54. doi: 10.1016/s0049-3848(00)00411-4.
Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.
Zhou X, Weeks SD, Ameloot P, Callewaert N, Strelkov SV, Declerck PJ.
J Thromb Haemost. 2016 Aug;14(8):1629-38. doi: 10.1111/jth.13381. Epub 2016 Jul 27.
Elucidating the molecular mechanisms of fibrinolytic shutdown after severe injury: The role of thrombin-activatable fibrinolysis inhibitor.
Coleman JR, Moore EE, Kelher MR, Jones K, Cohen MJ, Banerjee A, Silliman CC.
J Trauma Acute Care Surg. 2023 Jun 1;94(6):857-862. doi: 10.1097/TA.0000000000003911. Epub 2023 Feb 13.
Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a.
Semeraro F, Ammollo CT, Gils A, Declerck PJ, Colucci M.
J Thromb Haemost. 2013 Dec;11(12):2137-47. doi: 10.1111/jth.12431.
